GOLIMUMAB Human Anti-TNF-α Monoclonal Antibody Treatment of Inflammation

Golimumab (CNTO-148, Simponi (TM)) is a new human monoclonal-antibody under development by Centocor that targets and neutralizes the proinflammatory cytokine TNF-alpha This review summarizes in vitro and in vivo publications and highlights the clinical efficacy and safety data presented to dote (i.e., the CO-REVEAL, GO-RAISE, CO-FORWARD and GO-AFTER trials). These clinical findings have led to the recent approval of golimumab in Canada and the U.S. as a once-monthly S.C. treatment for adults with moderate to severe active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. A request for European approval has recently been submitted. Clinical trials ore also under way in ulcerative colitis.